speb/financial-data huggingface dataset:
GSK.L cash_flow (annual, 2024-12-31) — Change In Receivables: 340000000.00
GSK.L cash_flow (annual, 2024-12-31) — Change In Working Capital: 2090000000.00
GSK.L cash_flow (annual, 2024-12-31) — Changes In Cash: 599000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Common Stock: 1348000000.00
GSK.L cash_flow (annual, 2024-12-31) — Common Stock Dividend Paid: -2444000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Common Stock Equity: 13671000000.00
GSK.L cash_flow (annual, 2024-12-31) — Common Stock Issuance: 20000000.00
GSK.L cash_flow (annual, 2024-12-31) — Common Stock Payments: 0.00
GSK.L balance_sheet (annual, 2024-12-31) — Construction In Progress: 2320000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Construction In Progress: 2320000000.00
GSK.L income_statement (annual, 2024-12-31) — Cost Of Revenue: 9048000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Current Assets: 16997000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 168000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Current Capital Lease Obligation: 168000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Current Debt: 2181000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Current Debt: 2181000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 2349000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Current Liabilities: 21697000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Current Provisions: 1946000000.00
GSK.L cash_flow (annual, 2024-12-31) — Deferred Tax: 526000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Defined Pension Benefit: 898000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Defined Pension Benefit: 898000000.00
GSK.L cash_flow (annual, 2024-12-31) — Depreciation: 1097000000.00
GSK.L cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 2551000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Derivative Product Liabilities: 0.00
GSK.L income_statement (annual, 2024-12-31) — Diluted Average Shares: 4142000000.00
GSK.L income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 4145000000.00
GSK.L income_statement (annual, 2024-12-31) — Diluted EPS: 0.62
GSK.L income_statement (quarterly, 2024-12-31) — Diluted EPS: 0.10
GSK.L income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: 2575000000.00
GSK.L cash_flow (annual, 2024-12-31) — Dividends Received Cfi: 31000000.00
GSK.L cash_flow (quarterly, 2024-12-31) — Dividends Received Cfi: 0.00
GSK.L income_statement (annual, 2024-12-31) — EBIT: 4117000000.00
GSK.L income_statement (annual, 2024-12-31) — EBITDA: 6668000000.00
GSK.L cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: -54000000.00
GSK.L cash_flow (annual, 2024-12-31) — End Cash Position: 3403000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Financial Assets: 1000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 288000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 288000000.00
GSK.L cash_flow (annual, 2024-12-31) — Financing Cash Flow: -4726000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Finished Goods: 1625000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Finished Goods: 1625000000.00
GSK.L cash_flow (annual, 2024-12-31) — Free Cash Flow: 3572000000.00
GSK.L cash_flow (annual, 2024-12-31) — Gain Loss On Investment Securities: -10000000.00
GSK.L cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of Business: 5000000.00
GSK.L cash_flow (quarterly, 2024-12-31) — Gain Loss On Sale Of Business: 5000000.00
GSK.L cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of PPE: -170000000.00
GSK.L income_statement (annual, 2024-12-31) — General And Administrative Expense: 11015000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Goodwill: 6982000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 22497000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Gross Accounts Receivable: 5563000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Gross Accounts Receivable: 5563000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Gross PPE: 20556000000.00
GSK.L income_statement (annual, 2024-12-31) — Gross Profit: 22328000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Hedging Assets Current: 109000000.00
GSK.L income_statement (annual, 2024-12-31) — Interest Expense: 640000000.00
GSK.L income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 640000000.00
GSK.L income_statement (annual, 2024-12-31) — Interest Income: 60000000.00
GSK.L income_statement (annual, 2024-12-31) — Interest Income Non Operating: 60000000.00
GSK.L cash_flow (annual, 2024-12-31) — Interest Paid Cff: -632000000.00
GSK.L cash_flow (annual, 2024-12-31) — Interest Received Cfi: 138000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Inventory: 5669000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Invested Capital: 29555000000.00
GSK.L cash_flow (annual, 2024-12-31) — Investing Cash Flow: -1229000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Investmentin Financial Assets: 1136000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Investmentin Financial Assets: 1136000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Investmentsin Associatesat Cost: 96000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Investmentsin Associatesat Cost: 96000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Investmentsin Joint Venturesat Cost: 0.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Investmentsin Joint Venturesat Cost: 0.00
GSK.L cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 20000000.00
GSK.L cash_flow (annual, 2024-12-31) — Issuance Of Debt: 1341000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Land And Improvements: 6375000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Land And Improvements: 6375000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 934000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Long Term Capital Lease Obligation: 934000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Long Term Debt: 13703000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Long Term Debt: 13703000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 14637000000.00
GSK.L cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 1075000000.00
GSK.L cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -1615000000.00
GSK.L cash_flow (quarterly, 2024-12-31) — Long Term Debt Payments: -1615000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Long Term Equity Investment: 96000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Long Term Provisions: 589000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 11217000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 11217000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Minority Interest: -585000000.00
GSK.L income_statement (annual, 2024-12-31) — Minority Interests: -376000000.00
GSK.L cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 1368000000.00
GSK.L cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 20000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Net Debt: 12191000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Net Debt: 12191000000.00
GSK.L income_statement (annual, 2024-12-31) — Net Income: 2575000000.00
GSK.L income_statement (annual, 2024-12-31) — Net Income Common Stockholders: 2575000000.00
GSK.L income_statement (annual, 2024-12-31) — Net Income Continuous Operations: 2951000000.00
GSK.L income_statement (annual, 2024-12-31) — Net Income Discontinuous Operations: 0.00
GSK.L income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 2575000000.00
GSK.L income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 2575000000.00
GSK.L cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: 2951000000.00
GSK.L income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: 2951000000.00
GSK.L cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: -1452000000.00
GSK.L income_statement (annual, 2024-12-31) — Net Interest Income: -603000000.00
GSK.L cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: 21000000.00
GSK.L cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -1166000000.00
GSK.L cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -540000000.00
GSK.L income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: -603000000.00
GSK.L cash_flow (annual, 2024-12-31) — Net Other Financing Charges: 138000000.00
GSK.L cash_flow (annual, 2024-12-31) — Net Other Investing Changes: -1000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Net PPE: 10073000000.00
GSK.L cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -1334000000.00
GSK.L cash_flow (annual, 2024-12-31) — Net Short Term Debt Issuance: -626000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Net Tangible Assets: -8826000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Non Current Accrued Expenses: 6000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Non Current Accrued Expenses: 6000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Non Current Deferred Revenue: 165000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Non Current Deferred Revenue: 165000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Assets: 6757000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 382000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 1864000000.00
GSK.L income_statement (annual, 2024-12-31) — Normalized EBITDA: 8127000000.00
GSK.L income_statement (annual, 2024-12-31) — Normalized Income: 3813282714.98
GSK.L cash_flow (annual, 2024-12-31) — Operating Cash Flow: 6554000000.00
GSK.L income_statement (annual, 2024-12-31) — Operating Income: 5542000000.00
GSK.L income_statement (annual, 2024-12-31) — Operating Revenue: 31376000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 4080818273.00
GSK.L balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 1172000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Other Equity Interest: -397000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Other Equity Interest: -397000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 15515000000.00
GSK.L cash_flow (annual, 2024-12-31) — Other Non Cash Items: 398000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 6108000000.00
GSK.L income_statement (annual, 2024-12-31) — Other Operating Expenses: 9000000.00
GSK.L income_statement (quarterly, 2024-12-31) — Other Operating Expenses: -1177000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Other Payable: 420000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Other Payable: 420000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Other Properties: 8000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Other Receivables: 436000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Other Receivables: 436000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 21000000.00
GSK.L income_statement (annual, 2024-12-31) — Other Special Charges: -518000000.00
GSK.L income_statement (annual, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
GSK.L balance_sheet (annual, 2024-12-31) — Payables: 4585000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 125000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 125000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Prepaid Assets: 390000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Prepaid Assets: 390000000.00
GSK.L income_statement (annual, 2024-12-31) — Pretax Income: 3477000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Properties: 0.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
GSK.L cash_flow (annual, 2024-12-31) — Purchase Of Business: -988000000.00
GSK.L cash_flow (annual, 2024-12-31) — Purchase Of Intangibles: -1583000000.00
GSK.L cash_flow (annual, 2024-12-31) — Purchase Of PPE: -1399000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Raw Materials: 1361000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Raw Materials: 1361000000.00
GSK.L income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 9048000000.00
GSK.L income_statement (annual, 2024-12-31) — Reconciled Depreciation: 2551000000.00
GSK.L income_statement (annual, 2024-12-31) — Rent Expense Supplemental: 30000000.00
GSK.L cash_flow (annual, 2024-12-31) — Repayment Of Debt: -2507000000.00
GSK.L cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: 0.00
GSK.L income_statement (annual, 2024-12-31) — Research And Development: 6401000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Restricted Cash: 177000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Restricted Cash: 177000000.00
GSK.L income_statement (annual, 2024-12-31) — Restructuring And Mergern Acquisition: 1751000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Retained Earnings: 7796000000.00
GSK.L cash_flow (annual, 2024-12-31) — Sale Of Business: 2356000000.00
GSK.L cash_flow (annual, 2024-12-31) — Sale Of Intangibles: 131000000.00
GSK.L cash_flow (annual, 2024-12-31) — Sale Of Investment: 21000000.00
GSK.L cash_flow (annual, 2024-12-31) — Sale Of PPE: 65000000.00
GSK.L income_statement (annual, 2024-12-31) — Selling General And Administration: 11015000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Share Issued: 4314303734.00
GSK.L cash_flow (annual, 2024-12-31) — Short Term Debt Issuance: 266000000.00
GSK.L cash_flow (annual, 2024-12-31) — Short Term Debt Payments: -892000000.00
GSK.L income_statement (annual, 2024-12-31) — Special Income Charges: -1233000000.00
GSK.L income_statement (quarterly, 2024-12-31) — Special Income Charges: -1233000000.00
GSK.L cash_flow (annual, 2024-12-31) — Stock Based Compensation: 344000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Stockholders Equity: 13671000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Tangible Book Value: -8826000000.00
GSK.L income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -220717285.02
GSK.L income_statement (annual, 2024-12-31) — Tax Provision: 526000000.00
GSK.L income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.15
GSK.L balance_sheet (annual, 2024-12-31) — Taxes Receivable: 936000000.00
GSK.L cash_flow (annual, 2024-12-31) — Taxes Refund Paid: -1307000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Total Assets: 59463000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Total Capitalization: 27374000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Total Debt: 16986000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 13086000000.00
GSK.L income_statement (annual, 2024-12-31) — Total Expenses: 25834000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 46377000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 42466000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 24680000000.00
GSK.L income_statement (annual, 2024-12-31) — Total Operating Income As Reported: 4021000000.00
GSK.L income_statement (annual, 2024-12-31) — Total Other Finance Cost: 23000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Total Tax Payable: 703000000.00
GSK.L income_statement (annual, 2024-12-31) — Total Unusual Items: -1459000000.00
GSK.L income_statement (quarterly, 2024-12-31) — Total Unusual Items: -1459000000.00
GSK.L income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -1459000000.00
GSK.L income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: -1459000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Tradeand Other Payables Non Current: 929000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Tradeand Other Payables Non Current: 929000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Treasury Shares Number: 233485461.00
GSK.L balance_sheet (annual, 2024-12-31) — Work In Process: 2683000000.00
GSK.L balance_sheet (quarterly, 2024-12-31) — Work In Process: 2683000000.00
GSK.L balance_sheet (annual, 2024-12-31) — Working Capital: -4700000000.00
GSK.L income_statement (quarterly, 2025-03-31) — +Operating Expense: 3363000000.00
GSK.L income_statement (quarterly, 2025-03-31) — +Total Revenue: 7516000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 15149000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 7059000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 3484000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Assets Held For Sale Current: 4000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Basic Average Shares: 4088000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Basic EPS: 0.40
GSK.L cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 3403000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -448000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Capital Stock: 1349000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 4464000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 4485000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Cash Dividends Paid: -612000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -788000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Changes In Cash: 859000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Common Stock: 1349000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Common Stock Dividend Paid: -612000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 14157000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Common Stock Issuance: 12000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Common Stock Payments: -247000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 1937000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Current Assets: 18085000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 1958000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 20831000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Current Provisions: 1840000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Deferred Tax: 336000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Depreciation: 823000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 823000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Derivative Product Liabilities: 2000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 4137000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.39
GSK.L income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 1624000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Dividends Received Cfi: 0.00
GSK.L income_statement (quarterly, 2025-03-31) — EBIT: 2270000000.00
GSK.L income_statement (quarterly, 2025-03-31) — EBITDA: 3093000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: -11000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — End Cash Position: 4251000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Financial Assets: 0.00
GSK.L cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 858000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Free Cash Flow: 697000000.00
GSK.L income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 2070000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Goodwill: 6926000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 23184000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Gross PPE: 9971000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Gross Profit: 5579000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 95000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Interest Expense: 162000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 162000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Interest Income: 54000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 54000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Interest Paid Cff: -69000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Interest Received Cfi: 53000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Inventory: 6000000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Invested Capital: 14157000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -1144000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Issuance Of Capital Stock: 12000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Issuance Of Debt: 2077000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 16474000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Long Term Debt Issuance: 2018000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 99000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 555000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Minority Interest: -503000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Minority Interests: -148000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Net Business Purchase And Sale: -826000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: -235000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Net Income: 1624000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 1624000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 1772000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 1624000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 1624000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: 1772000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 1772000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Net Intangibles Purchase And Sale: -164000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Net Interest Income: -108000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 0.00
GSK.L cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: 1918000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: 2018000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -108000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -29000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Net PPE: 9971000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -207000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Net Short Term Debt Issuance: -100000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: -9027000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 6410000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 404000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 1870000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 3093000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Normalized Income: 1624000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: 1145000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Operating Income: 2216000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Operating Revenue: 7516000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 4084314542.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 1175000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 16258000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Other Investments: 933000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 108000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 2023000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 6884000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 11000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Other Properties: 9971000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 21000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Payables: 15777000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Pretax Income: 2108000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Purchase Of Business: -826000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Purchase Of Intangibles: -240000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -208000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 1937000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 823000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -159000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Repurchase Of Capital Stock: -247000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Research And Development: 1462000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 8307000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Sale Of Business: 0.00
GSK.L cash_flow (quarterly, 2025-03-31) — Sale Of Intangibles: 76000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Sale Of PPE: 1000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Selling General And Administration: 2070000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Share Issued: 4315221732.00
GSK.L cash_flow (quarterly, 2025-03-31) — Short Term Debt Issuance: 59000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Short Term Debt Payments: -159000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 14157000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: -9027000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
GSK.L income_statement (quarterly, 2025-03-31) — Tax Provision: 336000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.16
GSK.L balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 442000000.00
GSK.L cash_flow (quarterly, 2025-03-31) — Taxes Refund Paid: -156000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Total Assets: 60705000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 14157000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Total Debt: 18432000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 13654000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Total Expenses: 5300000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 47051000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 42620000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 26220000000.00
GSK.L income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: 2216000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 628000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Tradeand Other Payables Non Current: 31000000.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 230907190.00
GSK.L balance_sheet (quarterly, 2025-03-31) — Working Capital: -2746000000.00
GSK.L income_statement (quarterly, 2025-06-30) — +Operating Expense: 3798000000.00
GSK.L income_statement (quarterly, 2025-06-30) — +Total Revenue: 7986000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 14820000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 7321000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 3486000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Assets Held For Sale Current: 85000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Basic Average Shares: 4063000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Basic EPS: 0.36
GSK.L cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 4251000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -633000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Capital Stock: 1349000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 3599000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 3619000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Cash Dividends Paid: -656000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -1031000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Changes In Cash: -901000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Common Stock: 1349000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Common Stock Dividend Paid: -656000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 14791000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Common Stock Issuance: 2000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Common Stock Payments: -561000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 2165000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Current Assets: 17673000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 2050000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 20378000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Current Provisions: 1693000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Deferred Tax: 241000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Depreciation: 1159000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 1159000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Derivative Product Liabilities: 68000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 4110000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.35
GSK.L income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 1443000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Dividends Received Cfi: 0.00
GSK.L income_statement (quarterly, 2025-06-30) — EBIT: 2071000000.00
GSK.L income_statement (quarterly, 2025-06-30) — EBITDA: 3230000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: -26000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — End Cash Position: 3324000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Financial Assets: 0.00
GSK.L cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -2372000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 1463000000.00
GSK.L income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 2140000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Goodwill: 6734000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 22110000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Gross PPE: 9918000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Gross Profit: 5821000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Hedging Assets Current: 200000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Interest Expense: 184000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 184000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Interest Income: 50000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 50000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Interest Paid Cff: -256000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Interest Received Cfi: 39000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Inventory: 6072000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Invested Capital: 14791000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -625000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Issuance Of Capital Stock: 2000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Issuance Of Debt: 645000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 15304000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Long Term Debt Issuance: -35000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Long Term Equity Investment: 88000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Long Term Provisions: 575000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Minority Interest: -437000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Minority Interests: -203000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Net Business Purchase And Sale: -36000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: -559000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Net Income: 1443000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 1443000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 1646000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 1443000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 1443000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: 1646000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 1646000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Net Intangibles Purchase And Sale: -377000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Net Interest Income: -134000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: 0.00
GSK.L cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -874000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -1444000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -134000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: 148000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Net PPE: 9918000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -251000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Net Short Term Debt Issuance: 570000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: -7319000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Assets: 6581000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 384000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Non Current Pension And Other Postretirement Benefit Plans: 1752000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 3230000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Normalized Income: 1443000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 2096000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Operating Income: 2023000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Operating Revenue: 7986000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 4046397628.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Other Current Liabilities: 1134000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 15376000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Other Investments: 889000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 134000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 1999000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 6442000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Other Properties: 9918000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 20000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Payables: 15401000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Pretax Income: 1887000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Purchase Of Business: -54000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Purchase Of Intangibles: -377000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -256000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 2165000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 1159000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -1519000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Repurchase Of Capital Stock: -561000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Research And Development: 2024000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Retained Earnings: 8797000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Sale Of Business: 18000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Sale Of Intangibles: 0.00
GSK.L cash_flow (quarterly, 2025-06-30) — Sale Of PPE: 5000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Selling General And Administration: 2140000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Share Issued: 4315370199.00
GSK.L cash_flow (quarterly, 2025-06-30) — Short Term Debt Issuance: 680000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Short Term Debt Payments: -110000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 14791000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: -7319000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
GSK.L income_statement (quarterly, 2025-06-30) — Tax Provision: 241000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.13
GSK.L balance_sheet (quarterly, 2025-06-30) — Taxes Receivable: 376000000.00
GSK.L cash_flow (quarterly, 2025-06-30) — Taxes Refund Paid: -337000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Total Assets: 59258000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 14791000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Total Debt: 17354000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 14354000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Total Expenses: 5963000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 44904000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 41585000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 24526000000.00
GSK.L income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: 2023000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 581000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Tradeand Other Payables Non Current: 1000000.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Treasury Shares Number: 268972571.00
GSK.L balance_sheet (quarterly, 2025-06-30) — Working Capital: -2705000000.00
GSK.L income_statement (quarterly, 2025-09-30) — +Operating Expense: 3696000000.00
GSK.L income_statement (quarterly, 2025-09-30) — +Total Revenue: 8547000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 15675000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 7937000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 3486000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Assets Held For Sale Current: 7000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 3324000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -879000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Capital Stock: 1349000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 3296000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 3306000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Cash Dividends Paid: -650000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -206000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Changes In Cash: -624000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Common Stock: 1349000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Common Stock Dividend Paid: -650000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 16148000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: 0.00
GSK.L cash_flow (quarterly, 2025-09-30) — Common Stock Payments: -317000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 2258000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Current Assets: 17842000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 2856000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 21334000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Current Provisions: 1130000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Deferred Tax: 312000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Depreciation: 738000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 738000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Derivative Product Liabilities: 66000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 2013000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Dividends Received Cfi: 17000000.00
GSK.L income_statement (quarterly, 2025-09-30) — EBIT: 2623000000.00
GSK.L income_statement (quarterly, 2025-09-30) — EBITDA: 3361000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: 59000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — End Cash Position: 2759000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Financial Assets: 0.00
GSK.L cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -1315000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 1343000000.00
GSK.L income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 2239000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Goodwill: 7117000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 23982000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Gross PPE: 10132000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Gross Profit: 6289000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Hedging Assets Current: 107000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Interest Expense: 167000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 167000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Interest Income: 26000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 26000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Interest Paid Cff: -59000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Interest Received Cfi: 25000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Inventory: 6118000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Invested Capital: 16148000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -1531000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: 0.00
GSK.L cash_flow (quarterly, 2025-09-30) — Issuance Of Debt: -80000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 14894000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Long Term Debt Issuance: -4000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: 7000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Long Term Equity Investment: 129000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 673000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Minority Interest: -396000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Minority Interests: -131000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Net Business Purchase And Sale: -746000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: -317000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Net Income: 2013000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 2013000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 2144000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 2013000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 2013000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: 2144000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 2144000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Net Intangibles Purchase And Sale: -532000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Net Interest Income: -141000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 11000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -86000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: 3000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -141000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -48000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Net PPE: 10132000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -306000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Net Short Term Debt Issuance: -89000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: -7834000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 6168000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 390000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Non Current Pension And Other Postretirement Benefit Plans: 1663000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 3361000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Normalized Income: 2013000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 2222000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Operating Income: 2593000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Operating Revenue: 8547000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 4026337496.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 1236000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 16865000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Other Investments: 954000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 141000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 2132000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 6567000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Other Properties: 10132000000.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 10000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
GSK.L balance_sheet (quarterly, 2025-09-30) — Payables: 15999000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Pretax Income: 2456000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Purchase Of Business: -866000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Purchase Of Intangibles: -568000000.00
GSK.L cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -311000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 2258000000.00
GSK.L income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 738000000.00